Mechanistic basis of the acute safety profile of rese-cel, an autologous CD19-CAR T, in patients with autoimmune disease treated in four ongoing phase 1/2 clinical trials
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Daniel Nunez, Jenell Volkov, Dan Thompson, Fatemeh Hadi Nezhad, Domenick Braccia, Jason Stadanlick, Thomas Fumanak, Mallorie Werner, Zachary Vorndran, Larissa Ishikawa, Alexandra Ellis, Steve Flanagan, Jazmean Williams, Justin Cicarelli, Danielle Kobulsky, Quynh Lam, Courtney Little, Yvonne White, Saira Sheikh, Vimal Derebail, Natalie Grover, Gaurav Gulati, Mehrdad Abedi, Meghan Sise, Matthew Frigault, Christopher Palma, Patrick Reagan, Cuoghi Edens, Satyajit Kosuri, Caitlin Elgarten, Jon Burnham, Christina Ulane, Ran Reshef, Tahseen Mozaffar, Elie Naddaf, Nizar Chahin, Erin Wilfong, Dinesh Khanna, Monalisa Ghosh, Ankoor Shah, Jonathan Hogan, Rebecca Estremera, Raj Tummala, David Chang, Gwendolyn Binder, Samik Basu
Institutions: University of North Carolina at Chapel Hill, University of California, Davis, Massachusetts General Hospital, University of Rochester, University of Chicago, Children's Hospital of Philadelphia, Columbia University, University of California, Irvine, Mayo Clinic, Oregon Health & Science University, Vanderbilt University, University of Michigan, Duke University
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417015817
Cites:
Cited by:
Related to: